Hybrid cells producing monoclonal anti-CD14 antibodies
US7326569B2 · kind B2 · utility
5Cited by
4References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 2002 |
| Grant date | Feb 5, 2008 |
| Priority date | — |
| Expiry date | Feb 8, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/26
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.